We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lipomics Offers Comprehensive Acylcarnitine Profiling Assay
Product News

Lipomics Offers Comprehensive Acylcarnitine Profiling Assay

Lipomics Offers Comprehensive Acylcarnitine Profiling Assay
Product News

Lipomics Offers Comprehensive Acylcarnitine Profiling Assay


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Lipomics Offers Comprehensive Acylcarnitine Profiling Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lipomics Technologies, Inc. has announced the availability of an acylcarnitine profiling platform that will help accelerate the pace of drug discovery and development for a wide range of critical diseases and metabolic conditions.

Acylcarnitines are intermediates in mitochondrial beta-oxidation or "fat burning." Their measurement in serum or plasma provides information on changes in lipid metabolism related to obesity, exercise, stress response and myopathies.

The LC-MS based method provides quantitative data on short and long chain acylcarnitines as well as free carnitine.

"Quantitative acylcarnitine profiling provides an insight into changes in mitochondrial energetics influenced by disease, drug treatment and lifestyle," said chief scientific officer, Steve Watkins.

"Acylcarnitine profiling is an excellent complement to our existing assays. We can now provide our customers with a more comprehensive understanding of lipids and their role in metabolic diseases, enhancing all phases of pharmaceutical research from screening new compounds to clinical trials."

Advertisement